BeyondSpring Pharmaceuticals

BYSI · Nasdaq · United States

Share price · BYSI

$0.45-0.27 (-36.92%) 3M

close as of 2026-11-18 · 24h delayed · vol 53K (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BYSI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026-22.9%
  2. 2 Nov 2026+25.2%
  3. 30 Oct 2026+24.6%
  4. 29 Sep 2026-31.0%
  5. 28 Sep 2026+44.1%
  6. 10 Sep 2026+22.0%
  7. 17 Aug 2026-15.2%
  8. 14 Aug 2026-15.8%
  9. 13 Aug 2026+34.3%
  10. 10 Aug 2026-9.7%

Share of unusual movement by asset

For each asset, the share of BYSI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Plinabulin
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—5%
Other company news (earnings, financing, releases naming no asset)—12%
Sessions with no dated event—83%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Beta-tubulin (colchicine-site-adjacent binding site) / GEF-H1Small molecule
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
June 2029 (1)
PlinabulinPhase 3Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cance
Est. primary completion 2029-06-01 · NCT07361484 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 December 2021Complete response letterPlinabulinFDA issues complete response letter for the plinabulin NDA in chemotherapy-induced neutropenia
US, FDA · BeyondSpring Pharmaceuticals · Source ↗

Financial reports

Quarterly & interim (9)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$1.0M$2.7M+ $3.8M short-term inv.$0.8M-$3.8M operating cash flowreport ↗
View 8 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$0$1.1M$4.0M+ $3.8M short-term inv.$2.2M-$3.3M operating cash flowreport ↗
2025-Q3$0$1.0M$12M+ $0.1M short-term inv.$1.5M-$4.2M operating cash flowreport ↗
2025-Q2$0$1.0M$9.5M$1.8M-$5.9M operating cash flowreport ↗
2025-Q1$0$0.9M$6.5M+ $2.0M short-term inv.—-$4.2M operating cash flowreport ↗
2024-Q3$0$0.6M—$2.1M-$5.2M operating cash flowreport ↗
2024-Q2$0$0.8M$8.4M+ $6.0M short-term inv.$4.0M-$7.0M operating cash flowreport ↗
2024-Q1$0$0.7M—$3.2M-$5.3M operating cash flowreport ↗
2021-Q3$0.3M$8.5M$63M+ $28M short-term inv.$18M$2.8M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$4.4M$7.8M+ $4.8M short-term inv.$0.3M-$20M operating cash flowreport ↗

BeyondSpring reported revenue of $0M, unchanged YoY, with R&D spend of $4.39M, up 66.3% YoY. Cash and equivalents stood at $7.79M at year-end 2025. Net income/loss was not disclosed, and the quarterly net burn was $1.01M.

The company is advancing Plinabulin, its lead asset, including a planned NDA submission with China’s NMPA and a confirmatory global Phase 3 study in second- and third-line non-squamous NSCLC after progression on immune checkpoint inhibitors. Investigator-initiated studies in checkpoint-inhibitor-progressed cancers and first-line extensive-stage small cell lung cancer are ongoing. Its affiliate SEED Therapeutics advanced a novel RBM39 degrader into Phase 1 clinical studies in January 2026, supported by collaborations with Eli Lilly and Eisai.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$2.6M$2.9M+ $0 short-term inv.$2.8M-$16M operating cash flowreport ↗
2023-FY$0$7.3M$7.8M+ $0.2M short-term inv.$5.3M-$16M operating cash flowreport ↗
2022-FY$1.4M$26M$34M+ $2.9M short-term inv.$8.3M-$27M operating cash flowreport ↗
2021-FY$1.4M$37M$42M+ $31M short-term inv.$16M-$47M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-07-01Qiu Min · Chief Executive OfficerAward / grant (derivative)100,000——Form 4
2026-07-01Majeti Jiangwen · directorAward / grant (derivative)100,000——Form 4
2026-04-01Kirkby Matthew · directorAward / grant (derivative)23,902——Form 4
2026-04-01Xu Sihai · directorAward / grant (derivative)18,689——Form 4
2026-04-01Huang Lan · director, Chief Executive Officer, 10% ownerAward / grant (derivative)11,514——Form 4
2026-04-01Lu Yingjuan June · Chief Scientific OfficerAward / grant (derivative)17,840——Form 4
2026-04-01Majeti Jiangwen · directorAward / grant (derivative)21,730——Form 4
2026-04-01Delaney Brendan · directorAward / grant (derivative)20,427——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 20 reporting institutions held 6.0M shares ($9.8M, 14.6% of shares outstanding).

#InstitutionSharesValue
1Decheng Capital LLC3,800,702$6.2M
2BlackRock, Inc.649,462$1.1M
3VANGUARD CAPITAL MANAGEMENT LLC607,934$997K
4GEODE CAPITAL MANAGEMENT, LLC375,371$616K
5STATE STREET CORP231,120$379K
6VANGUARD FIDUCIARY TRUST CO179,925$295K
7NORTHERN TRUST CORP69,268$114K
8Meridian Wealth Management, LLC15,000$25K
9RENAISSANCE TECHNOLOGIES LLC11,100$18K
10Vanguard Global Advisers, LLC4,802$8K
11MORGAN STANLEY4,570$7K
12NATIONAL BANK OF CANADA /FI/2,875$5K
13Trifecta Capital Advisors, LLC1,500$2K
14UBS Group AG1,170$2K
15Tower Research Capital LLC (TRC)1,011$2K